Login
Products
Login
Home
Alerts
Search
Watchlist
Products

Nureca Ltd

NURECA
NSE
266.26
0.01%
Last Updated:
29 Apr '26, 4:00 PM
Company Overview
Alert
Watchlist
Note

Nureca Ltd

NURECA
NSE
266.26
0.01%
29 Apr '26, 4:00 PM
Company Overview
Add Alert
Add to Watchlist
Edit Note
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
254Cr
Close
Close Price
266.26
Industry
Industry
Trading
PE
Price To Earnings
24.61
PS
Price To Sales
1.77
Revenue
Revenue
143Cr
Rev Gr TTM
Revenue Growth TTM
51.02%
PAT Gr TTM
PAT Growth TTM
-284.40%
Peer Comparison
How does NURECA stack up?
Compare up to 10 companies side by side across valuation, profitability, and growth.
NURECA
VS

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Revenue
RevenueCr
212131221720312632343840
Growth YoY
Revenue Growth YoY%
-48.3-16.8-14.8-19.5-20.1-4.5-0.518.387.068.621.049.8
Expenses
ExpensesCr
252430272123343031353436
Operating Profit
Operating ProfitCr
-3-31-4-4-2-2-41-133
OPM
OPM%
-16.3-13.74.4-19.0-26.1-11.6-7.6-15.23.8-1.68.78.2
Other Income
Other IncomeCr
2336-16312322
Interest Expense
Interest ExpenseCr
000000001000
Depreciation
DepreciationCr
111111111111
PBT
PBTCr
-2-141-630-32155
Tax
TaxCr
0011-21000011
PAT
PATCr
-2-130-420-32144
Growth YoY
PAT Growth YoY%
-9.382.8200.0-43.3-171.2333.8-116.6-1,747.1159.5-51.2856.3233.2
NPM
NPM%
-7.2-3.39.20.8-24.48.2-1.5-10.67.82.49.69.4
EPS
EPS
-1.5-0.72.90.2-4.21.7-0.5-2.82.50.83.63.9

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue
RevenueCr
629921325611192110143
Growth
Revenue Growth%
60.6114.719.7-56.4-17.419.330.7
Expenses
ExpensesCr
5390152200126102117136
Operating Profit
Operating ProfitCr
9106256-15-10-87
OPM
OPM%
14.69.828.821.7-13.5-11.1-6.95.0
Other Income
Other IncomeCr
0038711129
Interest Expense
Interest ExpenseCr
01210012
Depreciation
DepreciationCr
00012222
PBT
PBTCr
996261-11-3113
Tax
TaxCr
321616-2-112
PAT
PATCr
664645-8-2111
Growth
PAT Growth%
2.7625.2-3.0-118.378.3147.21,157.7
NPM
NPM%
10.16.421.717.6-7.4-1.90.87.4
EPS
EPS
8.99.162.045.0-8.3-1.80.810.8

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital
Equity CapitalCr
00101010101010
Reserves
ReservesCr
815153193185183184189
Current Liabilities
Current LiabilitiesCr
15101912991224
Non Current Liabilities
Non Current LiabilitiesCr
09443332
Total Liabilities
Total LiabilitiesCr
2434186219207205210225
Current Assets
Current AssetsCr
2333181206187193190193
Non Current Assets
Non Current AssetsCr
1151320132032
Total Assets
Total AssetsCr
2434186219207205210225

Cash Flow

Consolidated
Standalone
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Operating Cash Flow
Operating Cash FlowCr
0-835110-3-19
Investing Cash Flow
Investing Cash FlowCr
00-110-3-16188
Financing Cash Flow
Financing Cash FlowCr
0892-7-2-10
Net Cash Flow
Net Cash FlowCr
0017-9-814-11
Free Cash Flow
Free Cash FlowCr
0-834-210-4-21
CFO To PAT
CFO To PAT%
4.9-123.975.23.1-124.0151.2-2,255.7
CFO To EBITDA
CFO To EBITDA%
3.4-81.756.72.5-68.126.6253.1

Ratios

Consolidated
Standalone
Financial YearMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
006021,362300255210
Price To Earnings
Price To Earnings
0.00.013.030.30.00.0247.5
Price To Sales
Price To Sales
0.00.02.85.32.72.81.9
Price To Book
Price To Book
0.00.03.76.71.51.31.1
EV To EBITDA
EV To EBITDA
0.01.07.823.1-15.5-20.8-22.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
35.135.053.448.132.134.138.0
OPM
OPM%
14.69.828.821.7-13.5-11.1-6.9
NPM
NPM%
10.16.421.717.6-7.4-1.90.8
ROCE
ROCE%
110.738.538.429.7-5.2-1.11.3
ROE
ROE%
78.442.828.422.1-4.2-0.90.4
ROA
ROA%
26.518.925.020.5-4.0-0.90.4
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
### **Overview** Nureca Ltd (NSE-listed) is a digital-first, debt-free healthcare and wellness company headquartered in India, operating under a scalable, asset-light business model. The company specializes in technology-enabled home healthcare, wellness, and medical devices, with a strategic shift from a product-centric to a service-driven, integrated **connected healthcare ecosystem**. Nureca’s primary brand is **Dr Trust**, complemented by **Dr Physio** (focused on pain management and mobility) and **Trumom** (mother and baby care). With over **1.34 crore products sold globally** and a strong digital presence across e-commerce and direct-to-consumer (D2C) platforms, Nureca has established itself as a trusted name in preventive and self-driven healthcare in India. --- ### **Business Model & Revenue Streams** - **Digital-First D2C Focus**: Over **93% of revenue (as of Oct 2025)** comes from online sales, primarily through: - E-commerce platforms (Amazon, Flipkart) - Own website: drtrust.in - Online pharmacy partners (e.g., 1mg) - **Quick Commerce Expansion**: Strategic partnerships with Blinkit, Swiggy Instamart, and Zepto enable **sub-30-minute delivery** in urban markets. Quick commerce is projected to contribute **15% of revenue by FY26**. - **Offline Growth**: The company has expanded to **23 out of 28 Indian states**, with **192+ active distributors**, a **52+ member sales team**, and presence in **22,000+ retail touchpoints** as of Q1 FY25. - **Emerging Channels**: Exports (currently <0.02% of turnover), corporate sales, and OEM manufacturing are being developed as new growth vectors. --- ### **Product Portfolio & Innovation** Nureca offers **102+ active SKUs** across five key categories: 1. **Chronic Disease Monitoring** - Digital BP monitors (e.g., BP iCheck Pro, Wrist Monitor), glucometers, pulse oximeters, ECG devices - Each of BP monitors, nebulizers, and self-monitoring blood glucose (SmBG) devices holds ~20% share in India’s chronic care device market. 2. **Mother & Baby Care (Trumom Brand)** - Breast pumps, sterilizers, baby scales, fetal dopplers - Niche innovations: *Mustard Seed Baby Head Shaping Pillow*, *Junior Compressor Nebulizer (pediatric)* 3. **Orthopedic & Pain Management (Dr Physio)** - TENS massagers, heat/cold therapy packs, heat belts, electric massagers (e.g., *Supervolt Octacore*), cervical/coccyx pillows 4. **Wellness & Lifestyle** - Smart scales (e.g., *8 Electrode Smart Scale*, *Legend Smart Scale*), thermometers (*InstaScan*, *Pet Thermometer*), sleep and travel aids (*Cloudwalker pillow*, *Yawnicorn Cuddle Pillow*) 5. **Nutrition & Supplements** - Glutathione, biotin, fish oil, *Jointrack®* (joint health), *Dr Trust Red Yeast* (heart health) **Recent Launches (FY25):** - Rechargeable Scalp Massager with Red Light Therapy - Pregnancy Support Pillow - Non-Contact Infrared Pet Thermometer - EpsoMAX (natural pain-relief body wash & foot cream) --- ### **Manufacturing & Supply Chain** - **Nureca Technologies Pvt Ltd (NTPL)**: Wholly owned, USFDA-registered (Reg. No. 3036779619) manufacturing subsidiary, operational since **April 2022** in Mohali, Punjab. - **Capabilities**: - Currently produces 32% of units in-house, reducing forex risk and lead times. - ISO 9001:2015 & ISO 13485:2016 certified. - 13 CDSCO approvals; 7 products with **USFDA 510(k)-exempt status**. - Products: BP monitors, nebulizers, thermometers, massagers, heating pads, breast pumps, stethoscopes. - **New Facility in Sundran, Punjab**: - 2.25-acre site under development, delayed due to statutory approvals. - Target capacity: **200,000–400,000 units/month**. - Will produce glucometers, strips, wheelchairs, orthopedic soft goods, and OEM devices. - **Integrated Ecosystem**: Leverages exclusive ancillary suppliers and mold vendors; achieves **45-day average manufacturing lead time**. --- ### **Connected Health Platform: Dr Trust 360** A cornerstone of Nureca’s strategic evolution, **Dr Trust 360** is a **freemium AI-powered connected health app** with **1.6 million active users (Aug 2025, +24% YoY)**. #### **Key Features** - **Free Tier**: - Blood pressure, heart rate, weight tracking - Historical trend analysis, smart reports - Smart OCR (Smart Sensei™) to digitize readings from non-connected devices - **Pro Subscription (Paid)**: - AI-generated personalized diet plans based on Dr Trust device data - Calorie & water intake tracking - HbA1c estimation - Family/caregiver alerts via WhatsApp - Advanced health reports and behavioral nudges #### **Integration & Use Cases** - Syncs with IoT-enabled devices: BP monitors, glucometers, smart scales, ECG, and wearable biosensors. - Enables **remote patient monitoring**, real-time alerts, and virtual doctor consultations. - Data shared via WhatsApp/email for caregivers and physicians. --- ### **Digital & Data-Centric Strategy** - **D2C Platform Investments**: Enhanced UI/UX, mobile apps (iOS/Android), influencer marketing, and customer service. - **Data-Driven Innovation**: - Informs product design, pricing, and feature optimization - Enables **personalized marketing, demand forecasting, and inventory management** - **Supply Chain Excellence**: Digitization has improved responsiveness, reduced lead times, optimized working capital, and lowered carrying costs. - **Marketing**: Uses AI and analytics for targeted campaigns, conversion improvement, and trend forecasting. --- ### **Competitive Advantage (Business Moat)** Nureca’s moat rests on the **synergy of Product, Placement, and Promotion**, supported by: - **Product**: 102+ SKUs, 102 design patents, USFDA & CE approvals - **Placement**: Pan-India reach via 192+ distributors, 22,000+ retail outlets, 1mg, and quick commerce - **Promotion**: Strong digital branding, over **131,000 positive online reviews**, high customer satisfaction - **Technology**: AI, IoT integration, and first-party data leverage - **Brand Equity**: **DrTrust** is a **"Well-Known Trademark"** in India --- ### **Strategic Pillars (as of Oct 2025)** 1. **Pan-India Sales Network Expansion**: Target expansion into all 28 states and top 500 cities. 2. **Manufacturing & Capacity Scaling**: Onboarding new facility in Punjab; targeting domestic and OEM/export markets. 3. **Connected Health Leadership**: Expand **Dr Trust 360** into a **one-stop virtual healthcare platform** with preventive and pre-diagnostic focus. --- ### **Financial & Operational Strengths** - **Debt-Free Balance Sheet**: No long-term borrowings; healthy liquidity. - **Asset-Light Model**: Capital efficient, high scalability. - **High Operating Leverage**: 67% ROCE in FY21; continued margin improvement targeted via AI-driven cost optimization. --- ### **Key Milestones & Recent Developments** - **Oct 2025**: Dr Trust 360 app hits 1.6M users; 93% revenue from online channels - **May 2025**: New Punjab facility approved; entry into contract manufacturing with pharma players - **Aug 2025**: Quick commerce drives incremental demand; offline presence at 10,000+ counters - **Jan 2025**: Cloudwalker pillow launch; roadmap to scale to 500+ cities - **Jun 2024**: Achieved "phygital" presence in 23 states; 1M+ D2C customers - **May 2022**: IPO listing on NSE/BSE; Dr Trust 360 platform launched - **Founded in 2016**, listed in **2021**, now serving over **1.34 crore customers** globally ---